Universitat Heidelberg

Running trials

• Recruiting

  Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis

  NCT06488625· Phase 2/3· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Source

• Active, not recruiting

  A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients with Breast Cancer

  NCT06112379· Phase 3· Source

• Recruiting

  A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)

  2023-507402-13-00· Phase 3· Source

• Recruiting

  A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

  NCT06163430· Phase 1/2· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· Source

• Active, not recruiting

  Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

  NCT06107413· Phase 2· Source

• Recruiting

  Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC

  2023-503558-10-00· Phase 3· Source

• Active, not recruiting

  A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

  NCT05676203· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Active, not recruiting

  A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

  NCT05794906· Phase 3· Source

• Recruiting

  Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

  NCT05551299· Phase 4· Source

• Active, not recruiting

  Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

  NCT05555732· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Source

• Active, not recruiting

  Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER-2 trial

  2023-507461-26-00· Phase 3· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Source

• Recruiting

  A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  NCT05304377· Phase 1· Source

• Recruiting

  A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT04928846· Phase 3· Source

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Source

• Recruiting

  Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  NCT04614103· Phase 2· Source

• Active, not recruiting

  Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

  NCT04246684· Phase 3· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Source

• Active, not recruiting

  Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

  NCT04309409· Phase 3· Source

• Active, not recruiting

  Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

  NCT04164901· Phase 3· Source

• Recruiting

  A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

  NCT03970447· Phase 2/3· Source

• Active, not recruiting

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· Phase 3· Source

• Active, not recruiting

  A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

  NCT03470922· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic myeloid leukaemia2 recruiting
• Crohn's disease1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Phase 4· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Source

• Active, not recruiting

  Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

  NCT05883644· Phase 3· Source

• Completed

  A study to see how well CVGBM vaccine works at different doses and how safe it is in patients who had surgery for glioblastoma or astrocytoma

  2022-501423-25-00· Phase 1/2· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Active, not recruiting

  First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

  NCT05527184· Phase 1· Source

• Completed

  Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that are postpubertal and/or adult consisting of lowering RT,chemotherapy doses and adding an investigative drug.

  NCT04402073· Phase 2· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Source

• Completed

  A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer

  NCT05328908· Phase 3· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· Source

• Completed

  Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

  NCT05097989· Phase 2· Source

• Completed

  A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease

  NCT04978493· Phase 2· Source

• Completed

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· Phase 3· Source

• Completed

  Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

  NCT04856085· Phase 2· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

  NCT03815058· Phase 2· Source

• Completed

  A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

  NCT02942290· Phase 1· Source